
Aytu BioScience AYTU
$ 2.17
-1.14%
Quarterly report 2026-Q3
added 05-13-2026
Aytu BioScience Accounts Receivables 2011-2026 | AYTU
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Aytu BioScience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.2 M | 23.5 M | 28.9 M | 21.7 M | 28.2 M | 5.18 M | 1.74 M | 579 K | 528 K | 162 K | 157 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.2 M | 157 K | 12.9 M |
Quarterly Accounts Receivables Aytu BioScience
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.5 M | 30.9 M | 33.2 M | 30.9 M | 33.2 M | 31.2 M | 35.8 M | 25.4 M | 23.2 M | 23.5 M | 29.9 M | 29.4 M | 29.9 M | 28.9 M | 34 M | 25.5 M | 27.9 M | 21.7 M | 27.6 M | 23 M | 21.6 M | 28.2 M | 28.2 M | 7 M | 6.11 M | 5.63 M | 5.18 M | 5.2 M | 1.71 M | 1.74 M | 1.74 M | 1.48 M | 760 K | 1.48 M | 579 K | 1.38 M | 1.21 M | 528 K | 528 K | 582 K | 509 K | 162 K | 162 K | 288 K | 168 K | 157 K | 157 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 35.8 M | 157 K | 14.7 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
73.6 K | - | 5743.5 % | $ 69.7 M | ||
|
Happiness Biotech Group Limited
HAPP
|
11.4 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
17.8 M | $ 1.66 | 2.8 % | $ 194 M | ||
|
I-Mab
IMAB
|
130 M | - | - | $ 866 M | ||
|
Compugen Ltd.
CGEN
|
61 M | $ 2.67 | -4.82 % | $ 249 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
28 K | $ 0.68 | -5.64 % | $ 31.1 M | ||
|
Esperion Therapeutics
ESPR
|
140 M | $ 3.13 | -0.16 % | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
11.8 M | $ 31.28 | -4.02 % | $ 842 M | ||
|
Berkeley Lights
BLI
|
18.5 M | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
1.22 M | - | - | $ 344 M | ||
|
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M | ||
|
Heron Therapeutics
HRTX
|
89.6 M | $ 0.87 | 1.36 % | $ 145 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
97 K | - | - | $ 384 M | ||
|
Anika Therapeutics
ANIK
|
23.7 M | $ 14.81 | -0.47 % | $ 212 M | ||
|
Advaxis
ADXS
|
234 K | - | -9.65 % | $ 45.9 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.7 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | ||
|
Aptinyx
APTX
|
257 K | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
3.27 M | - | -0.23 % | $ 916 M |